10/28
07:00 am
rdhl
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
Low
Report
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
10/22
07:00 am
rdhl
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
Medium
Report
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
10/14
07:00 am
rdhl
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
Medium
Report
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
10/1
07:00 am
rdhl
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
Medium
Report
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
9/30
07:00 am
rdhl
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
Low
Report
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
9/9
07:00 am
rdhl
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
Medium
Report
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
9/5
07:00 am
rdhl
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Low
Report
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
9/3
07:00 am
rdhl
New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
Low
Report
New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
8/29
07:00 am
rdhl
RedHill Biopharma Announces First Half 2024 Business Highlights
Low
Report
RedHill Biopharma Announces First Half 2024 Business Highlights
8/26
07:00 am
rdhl
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
Medium
Report
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
8/24
02:05 am
rdhl
RedHill Biopharma Ltd. (NASDAQ: RDHL) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
RedHill Biopharma Ltd. (NASDAQ: RDHL) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.